NASDAQ$SMLR

Semler Scientific Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Semler Scientific's Q1 2023 financial performance was marked by record quarterly revenues and pre-tax net income, driven predominately by sales of QuantaFlo for peripheral artery disease testing.

Semler Scientific reported a 30% increase in revenue, reaching $18.2 million, and a 48% increase in net income, amounting to $5.0 million for Q1 2023. The company's cash, cash equivalents, and short-term investments totaled $43.0 million.

  • Revenue increased by 30% to $18.2 million compared to Q1 2022.
  • Net income increased by 48% to $5.0 million compared to Q1 2022.
  • Cash, cash equivalents, and short-term investments totaled $43.0 million.
  • The company is focused on developing its business in heart dysfunction and diabetes.

Headline financials

Total Revenue

$18.2M

Previous: $14M+29.9%
EPS (adj)

$0.63

Previous: $0.41+53.7%
Capital Expenditures

$95K

Previous: $122K-22.1%
Free Cash Flow

$766K

Previous: $1.38M-44.5%
Net Income

$4.97M

Previous: $3.36M+47.9%
Operating Income

$6.26M

Previous: $3.94M+58.7%
Gross Profit

$16.9M

Previous: $13M+29.8%
Cash & Equivalents

$5.31M

Previous: $38.4M-86.2%
Total Assets

$70.3M

Previous: $55.4M+26.7%
Stock-Based Comp

$702K

Previous: $628K+11.8%

Revenue & EPS history

Semler Scientific · Revenue · Quarterly

$18.2M

Q1 2023+29.9%vs Q1 2022
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

Semler Scientific is focused on developing its business in two new disease areas, heart dysfunction and diabetes.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-0.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-5.8%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+33.6%

Q4 2014

Best reaction

-33.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-10.7%-16.0%-25.1%
Q2 2025-1.8%+2.0%-20.7%
Q1 2025-11.4%+17.9%-19.3%
Q4 2024+3.0%-12.4%-22.7%
Q3 2024+27.1%+29.9%+106.6%
Q2 2024-5.4%-1.7%-16.7%
Q4 2023-32.7%-36.8%-42.5%
Q3 2023+7.6%
Q2 2023+7.9%
Q1 2023+13.8%
Q4 2022+26.9%
Q3 2022-33.3%
Q2 2022+19.4%
Q1 2022-20.6%
Q4 2021-27.3%
Q3 2021-25.6%
Q2 2021-2.7%
Q1 2021+1.5%
Q4 2020+13.6%
Q3 2020+10.0%
Q2 2020-3.6%
Q1 2020-2.6%
Q4 2019+1.8%
Q3 2019+1.7%
Q2 2019+1.5%
Q1 2019-2.7%
Q4 2018+4.8%
Q3 2018-12.5%
Q2 2018+20.6%
Q1 2018+6.4%
Q4 2017+2.5%
Q3 2017+16.0%
Q2 2017-5.9%
Q1 2017+1.5%
Q4 2016+7.9%
Q3 2016-16.0%
Q2 2016+8.1%
Q1 2016-9.2%
Q4 2015-7.9%
Q3 2015+0.1%
Q2 2015-12.2%
Q1 2013+0.9%
Q4 2014+33.6%
Q3 2014-3.7%
Q2 2014-2.0%
Q1 2014+1.2%
Q4 2013
Q3 2013
Q2 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro